S
Stephan Hasmüller
Researcher at Ludwig Maximilian University of Munich
Publications - 15
Citations - 1341
Stephan Hasmüller is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Epirubicin & Breast cancer. The author has an hindex of 10, co-authored 15 publications receiving 1236 citations.
Papers
More filters
Journal ArticleDOI
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch,Peter A. Fasching,Gottfried E. Konecny,Stephan Hasmüller,Annette Lebeau,Rolf Kreienberg,Oumar Camara,Volkmar Müller,Andreas du Bois,Thorsten Kühn,Elmar Stickeler,Nadia Harbeck,Cornelia Höss,Steffen Kahlert,Thomas L. Beck,W Fett,Keyur Mehta,Gunter von Minckwitz,Sibylle Loibl +18 more
TL;DR: Neoadjuvant combination of trastuzumab and chemotherapy resulted in a high pCR rate in HER2-overexpressing primary breast cancer, and patients with a pCR after neoadjuant anti-HER2 therapy in combination with chemotherapy followed by maintenance trastzumab have an improved long-term outcome.
Journal ArticleDOI
Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
Philipp Kiewe,Stephan Hasmüller,Steffen Kahlert,Maja Heinrigs,Brigitte Rack,Alexander Marmé,Agnieszka Korfel,Michael Jäger,Horst Lindhofer,Harald Sommer,Eckhard Thiel,Michael Untch +11 more
TL;DR: Treatment with triple infusions of ertumaxomab yields a strong immunologic response and measurements of cytokines suggest a strong T helper cell type 1–associated immune response.
Journal ArticleDOI
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
Nadia Harbeck,Michael Schmitt,Christoph Meisner,C Friedel,Michael Untch,Martina Schmidt,C. G. J. F. Sweep,B. Lisboa,Michael P. Lux,Thomas M. Beck,Stephan Hasmüller,Marion Kiechle,Fritz Jänicke,C. Thomssen +13 more
TL;DR: Chemo-N0 is the first prospective biomarker-based therapy trial in early BC defining patients reaching good long-term DFS without adjuvant systemic therapy and these 10-year results support the guideline-based routine use of uPA/PAI-1 for risk-adapted individualised therapy decisions in N0 breast cancer.
Journal ArticleDOI
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery
Michael Untch,Peter A. Fasching,Gottfried E. Konecny,F. von Koch,U. Conrad,W Fett,Christian Kurzeder,H.-J. Lück,Elmar Stickeler,H. Urbaczyk,B Liedtke,Christoph Salat,Nadia Harbeck,V Müller,Martina Schmidt,Stephan Hasmüller,Miriam Lenhard,Tibor Schuster,Valentina Nekljudova,Annette Lebeau,S. Loibl,G. von Minckwitz +21 more
TL;DR: In this paper, patients were randomly allocated to either simultaneous darbepoetin alfa (DA) or none (n = 377), each 2-weekly and for three cycles.
Journal ArticleDOI
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis
Michael Untch,G. von Minckwitz,Gottfried E. Konecny,U. Conrad,W Fett,Christian Kurzeder,H.-J. Lück,Elmar Stickeler,H. Urbaczyk,B Liedtke,M. W. Beckmann,Christoph Salat,Nadia Harbeck,Volkmar Müller,Martina Schmidt,Stephan Hasmüller,Miriam Lenhard,Valentina Nekljudova,Annette Lebeau,S. Loibl,Peter A. Fasching +20 more
TL;DR: Neoadjuvant dose-intensified chemotherapy compared with standard chemotherapy did not improve DFS, whereas the addition of darbepoetin might have detrimental effects on DFS.